NASDAQ:DFFN - Diffusion Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.50
▼ -0.0049 (-0.97%)

This chart shows the closing price for DFFN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Diffusion Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DFFN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DFFN

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Diffusion Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.50.

This chart shows the closing price for DFFN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 1 polled investment analysts is to hold stock in Diffusion Pharmaceuticals. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/5/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/31/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/31/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/29/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/22/2021HC WainwrightReiterated RatingHoldLow
11/17/2020HC WainwrightDowngradeBuy ➝ NeutralHigh
8/12/2020HC WainwrightReiterated RatingBuy$3.50High
3/19/2020HC WainwrightReiterated RatingBuy$3.50High
12/18/2019HC WainwrightLower Price TargetBuy$10.00 ➝ $3.50Medium
3/20/2019HC WainwrightBoost Price TargetBuy$10.00Low
11/15/2018HC WainwrightSet Price TargetBuy$15.00High
8/20/2018HC WainwrightReiterated RatingBuy$18.75Medium
4/16/2018HC WainwrightSet Price TargetBuy$15.00High
3/21/2018HC WainwrightInitiated CoverageBuy ➝ Buy$18.75High
(Data available from 9/27/2016 forward)

News Sentiment Rating

0.75 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/29/2021
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/29/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/28/2021
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/27/2021

Current Sentiment

  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Diffusion Pharmaceuticals logo
Diffusion Pharmaceuticals, Inc. is a clinical stage company, which engages in the development of treatment for life threatening conditions. It offers Trans Sodium Crocetinate. The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, VA.
Read More

Today's Range

Now: $0.50
Low: $0.50
High: $0.51

50 Day Range

MA: $0.54
Low: $0.49
High: $0.61

52 Week Range

Now: $0.50
Low: $0.46
High: $1.85

Volume

6,311 shs

Average Volume

3,724,728 shs

Market Capitalization

$50.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.57

Frequently Asked Questions

What sell-side analysts currently cover shares of Diffusion Pharmaceuticals?

The following sell-side analysts have issued reports on Diffusion Pharmaceuticals in the last twelve months: HC Wainwright.
View the latest analyst ratings for DFFN.

What is the current price target for Diffusion Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Diffusion Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Diffusion Pharmaceuticals in the next year.
View the latest price targets for DFFN.

What is the current consensus analyst rating for Diffusion Pharmaceuticals?

Diffusion Pharmaceuticals currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in DFFN, but not buy more shares or sell existing shares.
View the latest ratings for DFFN.

What other companies compete with Diffusion Pharmaceuticals?

How do I contact Diffusion Pharmaceuticals' investor relations team?

Diffusion Pharmaceuticals' physical mailing address is 1317 CARLTON AVENUE SUITE 200, CHARLOTTESVILLE VA, 22902. The company's listed phone number is (434) 220-0718 and its investor relations email address is [email protected] The official website for Diffusion Pharmaceuticals is www.diffusionpharma.com.